Stock EIGR EIGER BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Market Closed - OTC Markets
Other stock markets
 03:59:47 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.67 USD -12.17% Intraday chart for Eiger BioPharmaceuticals, Inc. +11.72% -60.36%
Apr. 10 Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index CI
Apr. 08 Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Eiger BioPharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

bdfcd7442ee5716085.8Y2Pn6vELaTY-edTY7EE8aGYxwMuBNrhuhaOtiMy59Q.oOjCyPidZ8-7oa85B9N2mM7wsmlFZr-v3COj2UtdjrnHyvXM9LZE462Bpg~85dc68d57d9b18bd5e2d0cbcad2e58a8

Analyst Recommendations on Eiger BioPharmaceuticals, Inc.

News Highlights : Top Company News of the Day - Monday at 11 PM ET DJ
News Highlights : Top Company News of the Day - Monday at 7 PM ET DJ
Citigroup Adjusts Eiger BioPharmaceuticals Price Target to $3 From $4, Maintains Buy Rating MT
Baird Adjusts Price Target on Eiger BioPharmaceuticals to $5 From $3, Maintains Outperform Rating MT
BTIG Adjusts Eiger BioPharmaceuticals' Price Target to $48 from $57, Maintains Buy Rating MT
EIGER BIOPHARMACEUTICALS : Wedbush Suspended Coverage on Eiger BioPharmaceuticals MT
EIGER BIOPHARMACEUTICALS : Citigroup Adjusts Price Target on Eiger BioPharmaceuticals to $26 From $23, Maintains Buy Rating MT
EIGER BIOPHARMACEUTICALS : Wedbush Lifts Price Target for Eiger BioPharmaceuticals to $23 From $22, Maintains Outperform Rating MT
EIGER BIOPHARMACEUTICALS : Wedbush Adjusts Price Target for Eiger BioPharmaceuticals to $22 From $31, Maintains Outperform Rating MT
EIGER BIOPHARMACEUTICALS : Wedbush Adjusts Price Target on Eiger BioPharmaceuticals to $31 From $32, Keeps Outperform Rating MT
Eiger BioPharmaceuticals, Inc. Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to 'All-Oral' Lonafarnib-Ritonavir Regimen in Low Viral Load Hdv-Infected Patients At the International Liver Congress 2018 CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.67 USD
Average target price
30 USD
Spread / Average Target
+1,023.60%
High Price Target
30 USD
Spread / Highest target
+1,023.60%
Low Price Target
30 USD
Spread / Lowest Target
+1,023.60%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Eiger BioPharmaceuticals, Inc.

Citigroup
Baird
BTIG
Wedbush

Ratings for Eiger BioPharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. EIGR Stock
  4. Consensus Eiger BioPharmaceuticals, Inc.